Investigating how specific proteins affect liver health and diabetes.
Official title: Novel Roles of Cullin-RING E3 Ligases in Liver Pathophysiology
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11023068 · Data updated 2026-11-12
This study is looking at how certain proteins in the liver might help us understand and treat liver diseases like non-alcoholic fatty liver disease, especially for people dealing with obesity and type-2 diabetes, by finding new ways to improve insulin sensitivity and lower liver fat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | February 16, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $353,583 |
| NIH project number | 5R01DK134316-03 |
| Project ID | NIH-11023068 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-alcoholic fatty liver disease, obesity, or type-2 diabetes.
✕Less likely to help
Patients without liver disease or metabolic disorders may not benefit from this research.
What this research studies
This research focuses on understanding the role of Cullin-RING E3 ligases (CRLs) in liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and its association with obesity and type-2 diabetes. The researchers aim to explore how these ligases regulate lipid and glucose metabolism in the liver, which could lead to new therapeutic targets for treating these conditions. By studying the mechanisms of CRLs, the project seeks to identify potential drug targets that could improve insulin sensitivity and reduce liver fat accumulation. This research is particularly relevant for patients suffering from metabolic disorders linked to liver health.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve liver health and manage diabetes more effectively.
How similar studies have gone: Previous research has shown promise in targeting similar pathways for metabolic diseases, indicating potential for success in this approach.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Li, Tiangang — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Li, Tiangang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.